UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045188
Receipt number R000051622
Scientific Title Efficacy and safety of Anti-reflux mucosal ablation for refractory GERD: Multi-center prospective study.
Date of disclosure of the study information 2021/08/18
Last modified on 2021/08/18 16:43:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of Anti-reflux mucosal ablation for refractory GERD: Multi-center prospective study.

Acronym

Efficacy and safety of ARMA for GERD: Multi-center prospective study

Scientific Title

Efficacy and safety of Anti-reflux mucosal ablation for refractory GERD: Multi-center prospective study.

Scientific Title:Acronym

Efficacy and safety of ARMA for GERD: Multi-center prospective study

Region

Japan


Condition

Condition

PPI/PCAB refractory/dependent GERD

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effectiveness and safety of ARMA for refractory GERD patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Symptom scores(F scale,GERD-Q,GERD-HRQL,SF-36, Pittsburgh sleep quality index)

Key secondary outcomes

24h pH monitoring(Acid Exposure Time, DeMeester Composite Score, Number of acid exposure, All reflux episode, Symptom Index, Symptom Associated Possibility)
Endoscopic image (after 1-3 years)
24h pH monitoring (after 1-3 years)
Necessity of PPI/PCAB
EPSIS before and after ARMA
Adverse event: incidence of
bleeding, perforation, stenosis


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Place sub-circumferential endoscopic ablation at the gastric cardia utilizing Argon plasma coagulation(APC).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient with PPI/PCAB refractory/dependent GERD.

Key exclusion criteria

Inability or unwillingness of patients to give written informed consent.
Patient with prominent sliding hernia.
Patient with impaired esophageal motility.
Pregnancy.
Patient with psychiatric/Neurological disorders.
Patient with severe comorbidities.
Judged unsuitable for this study by the physicians

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Haruhiro
Middle name
Last name Inoue

Organization

Showa University Koto Toyosu Hospital

Division name

Digestive Diseases Center

Zip code

1358511

Address

5-1-38 Toyosu Koto-ku, Tokyo, Japan

TEL

08039002330

Email

mayo.tanabe@gmail.com


Public contact

Name of contact person

1st name Mayo
Middle name
Last name Tanabe

Organization

Showa University Koto Toyosu Hospital

Division name

Digestive Diseases Center

Zip code

1358511

Address

5-1-38 Toyosu Koto-ku, Tokyo, Japan

TEL

+81362046000

Homepage URL


Email

mayo.tanabe@gmail.com


Sponsor or person

Institute

Showa University Koto Toyosu Hospital, Digestive Diseases Center

Institute

Department

Personal name



Funding Source

Organization

Showa University Koto Toyosu Hospital, Digestive Diseases Center

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Fukuoka University Hospital
Tottori University Hospital
Osaka City University Hospital
Aichi Medical University Hospital
Shinshu University Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Showa University Koto Toyosu Hospital

Address

5-1-38 Toyosu Koto-ku, Tokyo, Japan

Tel

+81362046000

Email

th_irb@ofc.showa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 08 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2021 Year 08 Month 17 Day

Date of IRB

2021 Year 08 Month 17 Day

Anticipated trial start date

2021 Year 08 Month 17 Day

Last follow-up date

2027 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 08 Month 18 Day

Last modified on

2021 Year 08 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051622


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name